These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 26140474)

  • 1. A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome.
    Nimmerjahn F
    Eur J Immunol; 2015 Aug; 45(8):2183-90. PubMed ID: 26140474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vector-Mediated In Vivo Antibody Expression.
    Schnepp BC; Johnson PR
    Microbiol Spectr; 2014 Aug; 2(4):AID-0016-2014. PubMed ID: 26104192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-infection immunodeficiency virus control by neutralizing antibodies.
    Yamamoto H; Kawada M; Takeda A; Igarashi H; Matano T
    PLoS One; 2007 Jun; 2(6):e540. PubMed ID: 17579714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.
    Ali Tabei SM; Li Y; Weigert M; Dinner AR
    Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive immunization against HIV/AIDS by antibody gene transfer.
    Yang L; Wang P
    Viruses; 2014 Jan; 6(2):428-47. PubMed ID: 24473340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.
    Lu CL; Murakowski DK; Bournazos S; Schoofs T; Sarkar D; Halper-Stromberg A; Horwitz JA; Nogueira L; Golijanin J; Gazumyan A; Ravetch JV; Caskey M; Chakraborty AK; Nussenzweig MC
    Science; 2016 May; 352(6288):1001-4. PubMed ID: 27199430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-mediated prevention and treatment of HIV-1 infection.
    Gruell H; Klein F
    Retrovirology; 2018 Nov; 15(1):73. PubMed ID: 30445968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.
    Klein F; Halper-Stromberg A; Horwitz JA; Gruell H; Scheid JF; Bournazos S; Mouquet H; Spatz LA; Diskin R; Abadir A; Zang T; Dorner M; Billerbeck E; Labitt RN; Gaebler C; Marcovecchio P; Incesu RB; Eisenreich TR; Bieniasz PD; Seaman MS; Bjorkman PJ; Ravetch JV; Ploss A; Nussenzweig MC
    Nature; 2012 Dec; 492(7427):118-22. PubMed ID: 23103874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo.
    Deruaz M; Moldt B; Le KM; Power KA; Vrbanac VD; Tanno S; Ghebremichael MS; Allen TM; Tager AM; Burton DR; Luster AD
    J Infect Dis; 2016 Aug; 214(4):612-6. PubMed ID: 27357340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.
    Boesch AW; Alter G; Ackerman ME
    Curr Opin HIV AIDS; 2015 May; 10(3):160-9. PubMed ID: 25700208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in HIV-1 antibody research using humanized mice.
    Gruell H; Klein F
    Curr Opin HIV AIDS; 2017 May; 12(3):285-293. PubMed ID: 28422792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fc receptor but not complement binding is important in antibody protection against HIV.
    Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
    Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and characterization of chimeric and humanized forms of a broadly neutralizing monoclonal antibody to HIV-1.
    Major JG; Liou RS; Sun LK; Yu LM; Starnes SM; Fung MS; Chang TW; Chang NT
    Hum Antibodies Hybridomas; 1994; 5(1-2):9-17. PubMed ID: 7858187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities.
    Nimmerjahn F; Gordan S; Lux A
    Trends Immunol; 2015 Jun; 36(6):325-36. PubMed ID: 25981969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1.
    Jaworski JP; Cahn P
    Lancet HIV; 2018 Dec; 5(12):e723-e731. PubMed ID: 30245003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not Available].
    Gruell H; Klein F
    MMW Fortschr Med; 2015 Jun; 157 Suppl 2():46-9. PubMed ID: 26048121
    [No Abstract]   [Full Text] [Related]  

  • 17. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive hyperimmune therapy: a viable treatment option for the patient with acquired immune deficiency syndrome.
    Raven NC
    J Intraven Nurs; 1994; 17(4):214-6. PubMed ID: 7965365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV infection of monocytic cells: rôle of antibody-mediated virus binding to Fc-gamma receptors.
    Jouault T; Chapuis F; Olivier R; Parravicini C; Bahraoui E; Gluckman JC
    AIDS; 1989 Mar; 3(3):125-33. PubMed ID: 2523711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein.
    Kramski M; Stratov I; Kent SJ
    AIDS; 2015 Jan; 29(2):137-44. PubMed ID: 25396265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.